Potentials of Saponins-based Adjuvants for Nasal Vaccines

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2023 Apr 6

PMID 37020548

Authors

Kai Chen

Ning Wang

Xiaomin Zhang

Meng Wang

Yanyu Liu

Yun Shi

Affiliations

Soon will be listed here.

Abstract

Respiratory infections are a major public health concern caused by pathogens that colonize and invade the respiratory mucosal surface. Nasal vaccines have the advantage of providing protection at the primary site of pathogen infection, as they induce higher levels of mucosal secretory IgA antibodies and antigen-specific T and B cell responses. Adjuvants are crucial components of vaccine formulation that enhance the immunogenicity of the antigen to confer long-term and effective protection. Saponins, natural glycosides derived from plants, shown potential as vaccine adjuvants, as they can activate the mammalian immune system. Several licensed human vaccines containing saponins-based adjuvants administrated through intramuscular injection have demonstrated good efficacy and safety. Increasing evidence suggests that saponins can also be used as adjuvants for nasal vaccines, owing to their safety profile and potential to augment immune response. In this review, we will discuss the structure-activity-relationship of saponins, their important role in nasal vaccines, and future prospects for improving their efficacy and application in nasal vaccine for respiratory infection.

Citing Articles

Screening of aqueous plant extracts for immunomodulatory effects on immune cells and cytokine production: and analyses.

Dobutr T, Jangpromma N, Patramanon R, Daduang J, Kulchat S, Areemit J Heliyon. 2025; 11(4):e42692.

PMID: 40034324 PMC: 11872543. DOI: 10.1016/j.heliyon.2025.e42692.

Exploring the therapeutic potential of triterpenoid saponins from : Mechanistic insights into hepatoprotection, immunomodulation, anticancer activities, molecular docking, and pharmacokinetics.

Netala V, Hou T, Devarapogu R, Bethu M, Zhang Z, Vijaya T Heliyon. 2024; 10(23):e40850.

PMID: 39719988 PMC: 11666954. DOI: 10.1016/j.heliyon.2024.e40850.

Development of semisynthetic saponin immunostimulants.

Bai D, Kim H, Wang P Med Chem Res. 2024; 33(8):1292-1306.

PMID: 39132259 PMC: 11315725. DOI: 10.1007/s00044-024-03227-x.

Vaccine: Antigens and Mucosal Adjuvants.

Wang S, Yan T, Zhang B, Chen Y, Li Z Vaccines (Basel). 2024; 12(6).

PMID: 38932348 PMC: 11209493. DOI: 10.3390/vaccines12060619.

Outer membrane vesicles derived from are potent adjuvant that drive Th1-biased response.

Pschunder B, Locati L, Lopez O, Martin Aispuro P, Zurita E, Stuible M Front Immunol. 2024; 15:1387534.

PMID: 38650936 PMC: 11033331. DOI: 10.3389/fimmu.2024.1387534.

References

Coccia M, Collignon C, Herve C, Chalon A, Welsby I, Detienne S . Cellular and molecular synergy in AS01-adjuvanted vaccines results in an early IFNγ response promoting vaccine immunogenicity. NPJ Vaccines. 2017; 2:25. PMC: 5627273. DOI: 10.1038/s41541-017-0027-3. View

Solano-Parada J, Gonzalez-Gonzalez G, Torro L, dos Santos M, Espino A, Burgos M . Effectiveness of intranasal vaccination against Angiostrongylus costaricensis using a serine/threonine phosphatase 2 A synthetic peptide and recombinant antigens. Vaccine. 2010; 28(32):5185-96. DOI: 10.1016/j.vaccine.2010.05.072. View

Liu H, Patil H, De Vries-Idema J, Wilschut J, Huckriede A . Enhancement of the immunogenicity and protective efficacy of a mucosal influenza subunit vaccine by the saponin adjuvant GPI-0100. PLoS One. 2013; 7(12):e52135. PMC: 3524133. DOI: 10.1371/journal.pone.0052135. View

Kang L, Jing W, Liu J, Liu M . Trends of global and regional aetiologies, risk factors and mortality of lower respiratory infections from 1990 to 2019: An analysis for the Global Burden of Disease Study 2019. Respirology. 2022; 28(2):166-175. DOI: 10.1111/resp.14389. View

Shirahata T, Nagai T, Hirata N, Yokoyama M, Katsumi T, Konishi N . Syntheses and mucosal adjuvant activity of simplified oleanolic acid saponins possessing cinnamoyl ester. Bioorg Med Chem. 2017; 25(6):1747-1755. DOI: 10.1016/j.bmc.2016.09.052. View

Andersen C, Dietrich J, Agger E, Lycke N, Lovgren K, Andersen P . The combined CTA1-DD/ISCOMs vector is an effective intranasal adjuvant for boosting prior Mycobacterium bovis BCG immunity to Mycobacterium tuberculosis. Infect Immun. 2006; 75(1):408-16. PMC: 1828435. DOI: 10.1128/IAI.01290-06. View

Hellfritzsch M, Scherliess R . Mucosal Vaccination via the Respiratory Tract. Pharmaceutics. 2019; 11(8). PMC: 6723941. DOI: 10.3390/pharmaceutics11080375. View

Estrada A, Li B, Laarveld B . Adjuvant action of Chenopodium quinoa saponins on the induction of antibody responses to intragastric and intranasal administered antigens in mice. Comp Immunol Microbiol Infect Dis. 1998; 21(3):225-36. DOI: 10.1016/s0147-9571(97)00030-1. View

Sun T, Yan X, Guo W, Zhao D . Evaluation of cytotoxicity and immune modulatory activities of soyasaponin Ab: an in vitro and in vivo study. Phytomedicine. 2014; 21(13):1759-66. DOI: 10.1016/j.phymed.2014.09.002. View

10.

Dendouga N, Fochesato M, Lockman L, Mossman S, Giannini S . Cell-mediated immune responses to a varicella-zoster virus glycoprotein E vaccine using both a TLR agonist and QS21 in mice. Vaccine. 2012; 30(20):3126-35. DOI: 10.1016/j.vaccine.2012.01.088. View

11.

Pabst R . Mucosal vaccination by the intranasal route. Nose-associated lymphoid tissue (NALT)-Structure, function and species differences. Vaccine. 2015; 33(36):4406-13. DOI: 10.1016/j.vaccine.2015.07.022. View

12.

Christensen D, Polacek C, Sheward D, Hanke L, Moliner-Morro A, McInerney G . Protection against SARS-CoV-2 transmission by a parenteral prime-Intranasal boost vaccine strategy. EBioMedicine. 2022; 84:104248. PMC: 9448948. DOI: 10.1016/j.ebiom.2022.104248. View

13.

Duong V, Nguyen T, Maeng H . Recent Advances in Intranasal Liposomes for Drug, Gene, and Vaccine Delivery. Pharmaceutics. 2023; 15(1). PMC: 9865923. DOI: 10.3390/pharmaceutics15010207. View

14.

Morein B, Sundquist B, Hoglund S, Dalsgaard K, Osterhaus A . Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses. Nature. 1984; 308(5958):457-60. DOI: 10.1038/308457a0. View

15.

Sia Z, Chiem K, Huang W, Seffouh A, Teimouri Dereshgi A, Hogan T . Respiratory Vaccination with Hemagglutinin Nanoliposomes Protects Mice from Homologous and Heterologous Strains of Influenza Virus. J Virol. 2022; 96(19):e0100622. PMC: 9555155. DOI: 10.1128/jvi.01006-22. View

16.

Nakahashi-Ouchida R, Fujihashi K, Kurashima Y, Yuki Y, Kiyono H . Nasal vaccines: solutions for respiratory infectious diseases. Trends Mol Med. 2022; 29(2):124-140. DOI: 10.1016/j.molmed.2022.10.009. View

17.

Hu K, Lovgren-Bengtsson K, Morein B . Immunostimulating complexes (ISCOMs) for nasal vaccination. Adv Drug Deliv Rev. 2001; 51(1-3):149-59. DOI: 10.1016/s0169-409x(01)00165-x. View

18.

Ma X, Chi X, Yuan L, Wang Y, Li Z, Xu W . Immunomodulatory effect of ginseng stem-leaf saponins and selenium on Harderian gland in immunization of chickens to Newcastle disease vaccine. Vet Immunol Immunopathol. 2020; 225:110061. DOI: 10.1016/j.vetimm.2020.110061. View

19.

Alving C, Peachman K, Matyas G, Rao M, Beck Z . Army Liposome Formulation (ALF) family of vaccine adjuvants. Expert Rev Vaccines. 2020; 19(3):279-292. PMC: 7412170. DOI: 10.1080/14760584.2020.1745636. View

20.

Dehghan S, Kheiri M, Abnous K, Eskandari M, Tafaghodi M . Preparation, characterization and immunological evaluation of alginate nanoparticles loaded with whole inactivated influenza virus: Dry powder formulation for nasal immunization in rabbits. Microb Pathog. 2017; 115:74-85. DOI: 10.1016/j.micpath.2017.12.011. View